If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

Fri, 09th Feb 2024 17:02

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

The divergence between markets in Europe and New York was perhaps typified by the S&P 500 hitting a record high, cementing its status above the 5,000 point threshold.

The greenback ended the week by returning gains, meanwhile, as a government release denoting consumer price index reading revisions offered little to dollar bulls.

The FTSE 100 index closed down 22.90 points, 0.3%, at 7,572.58. The FTSE 250 ended 40.40 points lower, 0.2%, at 19,062.32, and the AIM All-Share lost 3.69 points, 0.5%, at 747.41.

For the week, both the FTSE 100 and FTSE 250 lost 0.6%, while the AIM All-Share gave back 0.9%

The Cboe UK 100 ended down 0.3% at 756.87, the Cboe UK 250 fell 0.5% to 16,463.05, and the Cboe Small Companies lost 0.3% to 14,534.93.

In European equities on Friday, both the CAC 40 in Paris and the DAX 40 in Frankfurt ended down 0.2%.

In New York, the Dow Jones Industrial Average was down 0.13%, while the S&P 500 added 0.3% and the Nasdaq Composite surged 0.9%.

Having very briefly topped the threshold on Thursday, the S&P 500 opened above 5,000 points on Friday.

"While the Nasdaq 100 and S&P 500 are making new record highs, the latter topping the 5,000 mark, European stock indices found it difficult to keep up and have had a slightly negative end to the week. The FTSE 100 in particular suffered a third straight day of losses ahead of next week's UK unemployment, inflation, Q4 GDP and retail sales data," IG analyst Axel Rudolph commented.

The unemployment, inflation and economic growth readings will be closely eyed by the Bank of England, with the next interest rate decision from Threadneedle Street around six weeks away.

The UK inflation data is released on Wednesday, though there is another reading before the BoE's next decision on March 20.

US inflation data for January is released on Tuesday. According to consensus cited by FXStreet, the annual consumer price inflation rate is expected to have cooled to 3.0% in January, from 3.4% in December.

US inflation data from the end of last year saw little in the way of revisions, according to new data published Friday.

The Bureau of Labor Statistics made minimal revisions to last year's inflation data, with consumer prices excluding food and energy items rising at a 3.3% annualised rate in the final three months of 2023, matching the previous reading.

Revisions to the headline figure were also minimal. December's monthly increase was marked down to a 0.2% advance instead of 0.3%, while the reading for November moved up 0.1 percentage point, also to 0.2%.

The dollar fell back after the figures, which were seen as supporting an interest rate cut in May.

Federal Reserve Chair Jerome Powell and his colleagues have said they need to see more evidence that price pressures are sustainably receding before they begin cutting interest rates.

In late January, Powell eroded hopes for a cut in interest rates in March, saying it is not the "most likely case."

The pound was quoted at USD1.2632 late on Friday in London, up compared to USD1.2609 at the equities close on Thursday. The euro stood at USD1.0783, up against USD1.0763. Against the yen, the dollar was trading at JPY149.31, down from JPY149.39.

In London, there was little in the way of major large-cap moves, with Fresnillo closing among the worst FTSE 100 performers. The gold miner ended down 3.4%, tracking bullion prices lower.

"After a barrage of company announcements this week, it's no wonder that markets have paused for breath on Friday. Investors have had so much to take in from a wealth of big names that they're exhausted by the all the numbers," AJ Bell analyst Russ Mould commented.

Gold was quoted at USD2,021.73 an ounce late Friday afternoon, down against USD2,029.31 late Thursday and off the USD2,034.63 it fetched this time last week. Gold traded as low as below the USD2,015 mark earlier this week.

ACY Securities analyst Luca Santos commented: "Gold, the age-old symbol of wealth and stability, has recently faced a significant challenge, breaking below a crucial technical support level at USD2.017 per ounce. This development sends a negative signal for both gold and silver. There is even a possibility of a further slide to the mid USD1.980 per ounce level, indicating a challenging period for gold investors."

Recently the object of takeover interest, packaging firm DS Smith and housebuilder Redrow climbed 2.5% and 0.3%, extending gains. Peer Mondi is mulling a takeover of DS Smith, while Redrow has agreed to a housebuilding tie-up with Barratt Developments.

There was some more dealmaking on Friday.

Barclays is to buy the retail banking business of Tesco Bank, as the big UK supermarkets scale back their forays into financial services.

Tesco said it will sell to Barclays all of its banking operations in credit cards, loans and savings to Barclays, while retaining other activities of Tesco Bank including insurance, automatic teller machines, travel money and gift cards. The supermarket noted that these businesses are capital-light, profitable, and have a strong connect to its core retail offer.

Barclays will pay about GBP600 million for the business, which has been in operation for more than 25 years. Tesco noted it will receive about GBP1 billion in cash in total, including a special dividend of GBP250 million paid by Tesco Bank back in August.

Tesco shares closed marginally higher, while Barclays fell 0.6% in a tricky day for London-listed lenders.

HSBC shares fell 1.3%, weighing on the FTSE 100. NatWest, meanwhile, gave back 2.2%, before it reports annual results next week Friday.

Elsewhere in London, AIM-listed Evgen Pharma slumped 22% as it announced it has issued a notice of dispute with partner Stalicla, explaining that it has not received funds it believes it is entitled to.

"In October 2022, Evgen licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study.

"The phase 1b human volunteer study was completed and the clinical study report finalised in August 2023."

Evgen said it believes the "payment is now due".

"In order to effect the payment, Evgen has taken the decision to formally implement the dispute resolution process detailed in the License Agreement, the first step of which is the issuance of a dispute notice. As stated in the half year results in October 2023, Evgen has not anticipated any milestone payments from Stalicla in its financial forecasting and its cash runway remains unchanged," it added.

Brent oil was quoted at USD82.03 a barrel late in London on Friday, up from USD81.02 late Thursday.

On Monday, financial markets in Shanghai and Tokyo are closed for the Chinese New Year and National Day holidays, respectively.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
2 Aug 2023 10:09

AIM WINNERS & LOSERS: Deltex plummets on return to AIM; Blancco rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
13 Jul 2023 15:58

UK shareholder meetings calendar - next 7 days

Friday 14 July 
Templeton Emerging Markets Investment Trust PLCAGM
Monday 17 July 
All ThingsConsidered Group PLCAGM
Tower Resources PLCAGM
Tuesday 18 July 
Alkemy Capital Investments PLCAGM
Bloomsbury Publishing PLCAGM
CT Property Trust LtdGM re takeover by LondonMetric Property
e-Therapeutics PLCAGM
MobilityOne LtdEGM re Tete planned JV deadline extension
SmartSpace Software PLCAGM
Strategic Minerals PLCAGM
Wynnstay Properties PLCAGM
Wednesday 19 July 
Berkeley Energia LtdAGM
Caledonian Trust PLCAGM
DG Innovate PLCAGM
Experian PLCAGM
HICL Infrastructure PLCAGM
Mind Gym PLCAGM
Sportech PLCGM re share capital restructure
Triple Point Income VCT PLCAGM
Thursday 20 July 
ACG Acquisition Co LtdEGM re acquisition of the Atlantic Nickel
Big Yellow Group PLCAGM
CT UK High Income Trust PLCAGM
Evgen Pharma PLCAGM
FD Technologies PLCAGM
Fuller, Smith & Turner PLCAGM
GB Group PLCAGM
Halma PLCAGM
Intermediate Capital Group PLCAGM
International Distributions Services PLCAGM
Fidelity China Special Situations PLCAGM
Johnson Matthey PLCAGM
Kingspan Group PLCEGM re delisting
Pennon Group PLCAGM
Premier Foods PLCAGM
Premier Miton Group PLCAGM
Qinetiq Group PLCAGM
SSE PLCAGM
TR Property Investment Trust PLCAGM
VP PLCAGM
Weiss Korea Opportunity Fund LtdAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
27 Jun 2023 10:17

AIM WINNERS & LOSERS: Unbound shares drop as calls off sales process

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
27 Jun 2023 10:01

Evgen Pharma's SFX-01 has positive effects for treating a rare cancer

(Alliance News) - Evgen Pharma PLC on Tuesday said its lead asset SFX-01 has radio-sensitising effects in vivo in a form of soft tissue sarcoma, as part of its research partnership with Sapienza University of Rome.

Read more
19 Jun 2023 10:05

Evgen collaborator receives grant from KWF Dutch Cancer Society

(Alliance News) - Evgen Pharma PLC on Monday said its collaborator at the Erasmus University Medical Center in Rotterdam has received notice of a grant from KWF Dutch Cancer Society.

Read more
7 Jun 2023 11:41

Evgen Pharma confident amid Stalicla deal; CFO Moulson to retire

(Alliance News) - Evgen Pharma PLC on Wednesday reported a widened annual loss and said its Chief Financial Officer Richard Moulson will retire in late July.

Read more
31 May 2023 15:46

UK earnings, trading statements calendar - next 7 days

Thursday 1 June 
Auto Trader Group PLCFull Year Results
Dr Martens PLCFull Year Results
Pennon Group PLCFull Year Results
Trinity Exploration & Production PLCFull Year Results
Friday 2 June 
TR Property Investment Trust PLCFull Year Results
Nostrum Oil & Gas PLCFull Year Results
Monday 5 June 
Celadon Pharmaceuticals PLCFull Year Results
Hercules Site Services PLCHalf Year Results
Itaconix PLCFull Year Results
Sirius Real Estate LtdFull Year Results
ValiRx PLCFull Year Results
Verici Dx PLCFull Year Results
Tuesday 6 June 
British American Tobacco PLCTrading Statement
Chemring Group PLCHalf Year Results
Ferguson PLCQ3 Results
Gooch & Housego PLCHalf Year Results
Jadestone Energy PLCFull Year Results
N Brown Group PLCFull Year Results
NewRiver REIT PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Paragon Banking Group PLCHalf Year Results
Speedy Hire PLCFull Year Results
Warehouse REIT PLCFull Year Results
Wednesday 7 June 
discoverIE Group PLCFull Year Results
Evgen Pharma PLCFull Year Results
LXi REIT PLCFull Year Results
Ramsdens Holdings PLCHalf Year Results
Residential Secure Income PLCHalf Year Results
Vp PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 Mar 2023 11:10

IN BRIEF: Evgen Pharma shares up as pharmacokinetic data announced

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focusing on sulforaphane-based medicines - Presents top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. Says the study is aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says SFX-01 shows no serious adverse effects and the study is on schedule for full reporting in the second quarter.

Read more
22 Mar 2023 10:30

AIM WINNERS & LOSERS: Pathfinder finds way forward in Mozambique

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
16 Mar 2023 16:35

Evgen notes evidence of radiosensitisation by SFX-01 in cancer cells

(Alliance News) - Evgen Pharma PLC said on Thursday it had found further evidence of radiosensitisation by SFX-01 in sarcoma cells.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
25 Jan 2023 10:40

Evgen Pharma completes dosing of clinical trial for SFX-01 tablet

(Alliance News) - Evgen Pharma PLC on Wednesday said it completed the dosing of all three cohorts of the phase 1/1b clinical trial of its SFX-01 tablet formulation.

Read more
8 Dec 2022 13:57

Evgen Pharma loss, operating expenses widen; SFX-01 study on schedule

(Alliance News) - Evgen Pharma PLC on Thursday said interim loss widened, but noted the healthy volunteer study of its SFX-01 formulation remains on schedule.

Read more
16 Nov 2022 16:11

Evgen Pharma starts clinical trial of new SFX-01 tablet

(Alliance News) - Evgen Pharma PLC said on Wednesday it had started a randomised, placebo-controlled clinical trial of its new SFX-01 tablet.

Read more
16 Nov 2022 14:05

Evgen Pharma doses first volunteers in SFX-01 trial

(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.